Bio Essence swings to Q2 FY26 profit of $270,077; revenue more than doubles to $794,711
BIOE•Costs and cash flow
General and administrative costs edged down 3.07% to $293,849, while selling expense fell 97.73% to $680. Operating cash flow turned to an outflow of $352,320, while cash and equivalents were $675 at quarter-end with a 0.38:1 current ratio.
Share issuance and lease dispute
Separately, the company issued 7,000,000 shares valued at $3.5 million to buy MediFlow AI software, while accruing about $1.5 million for a lease dispute.
Quarterly profit and revenue surge
Bio Essence posted net income of $270,077 for the quarter, swinging from a loss a year earlier. Revenue more than doubled to $794,711.
Six-month results improved sharply
For the six months ended June 30, 2026, Bio Essence posted net income of $475,450, swinging from a loss a year earlier. Revenue climbed to , up year over year, driven by higher OEM service orders including large orders from two new customers.
